Cell Applications Introduces Cellular Disease Model for Type 2 Diabetes
SAN DIEGO, Dec 11, 2015 -- Building on the success of their rheumatoid and osteoarthritis cells, Cell Applications, Inc. announces the launch of human cellular disease models for Type 2 Diabetes (T2D). The product grouping consists of human aortic endothelial cells, aortic smooth muscle cells, preadipocytes and skeletal muscle cells isolated from tissues of patient donors afflicted with the disease, where genetics and lifestyle factors contribute to insulin resistance. In addition to high blood sugar levels, the nearly 1 in 10 affected individuals can encounter complications including high blood pressure and cholesterol, heart attack, stroke, blindness, kidney disease, pregnancy problems, amputation and in severe cases, death. The expansion provides new primary cell-based options for life science research and pharmaceutical drug discovery. Company officials indicate additional disease models can be generated on a Custom Service basis.
Press & Media Relations
Daniel Schroen, PhD
VP, Sales & Marketing